157 related articles for article (PubMed ID: 34207464)
1. The Enhanced Efficacy of Intracellular Delivery of Doxorubicin/C6-Ceramide Combination Mediated by the F3 Peptide/Nucleolin System Is Supported by the Downregulation of the PI3K/Akt Pathway.
Cruz AF; Caleiras MB; Fonseca NA; Gonçalves N; Mendes VM; Sampaio SF; Moura V; Melo JB; Almeida RD; Manadas B; Simões S; Moreira JN
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34207464
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination.
Fonseca NA; Gomes-da-Silva LC; Moura V; Simões S; Moreira JN
J Control Release; 2014 Dec; 196():122-31. PubMed ID: 25305563
[TBL] [Abstract][Full Text] [Related]
3. Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination.
Fonseca NA; Rodrigues AS; Rodrigues-Santos P; Alves V; Gregório AC; Valério-Fernandes Â; Gomes-da-Silva LC; Rosa MS; Moura V; Ramalho-Santos J; Simões S; Moreira JN
Biomaterials; 2015 Nov; 69():76-88. PubMed ID: 26283155
[TBL] [Abstract][Full Text] [Related]
4. Modelling the impact of nucleolin expression level on the activity of F3 peptide-targeted pH-sensitive pegylated liposomes containing doxorubicin.
Lopes R; Shi K; Fonseca NA; Gama A; Ramalho JS; Almeida L; Moura V; Simões S; Tidor B; Moreira JN
Drug Deliv Transl Res; 2022 Mar; 12(3):629-646. PubMed ID: 33860446
[TBL] [Abstract][Full Text] [Related]
5. Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: In Vitro Evaluation on HeLa, A2780-ADR, and H69-AR Cells.
Sriraman SK; Pan J; Sarisozen C; Luther E; Torchilin V
Mol Pharm; 2016 Feb; 13(2):428-37. PubMed ID: 26702994
[TBL] [Abstract][Full Text] [Related]
6. Targeted liposomal doxorubicin/ceramides combinations: The importance to assess the nature of drug interaction beyond bulk tumor cells.
Cruz AF; Fonseca NA; Malheiro AR; B Melo J; Gaspar MM; Fernandes R; Moura V; Simões S; Moreira JN
Eur J Pharm Biopharm; 2022 Mar; 172():61-77. PubMed ID: 35104605
[TBL] [Abstract][Full Text] [Related]
7. Nucleolin is expressed in patient-derived samples and glioblastoma cells, enabling improved intracellular drug delivery and cytotoxicity.
Balça-Silva J; do Carmo A; Tão H; Rebelo O; Barbosa M; Moura-Neto V; Sarmento-Ribeiro AB; Lopes MC; Moreira JN
Exp Cell Res; 2018 Sep; 370(1):68-77. PubMed ID: 29902537
[TBL] [Abstract][Full Text] [Related]
8. Rapid liposomal formulation for nucleolin targeting to rhabdomyosarcoma cells.
Dzhumashev D; Anton-Joseph S; Morel VJ; Timpanaro A; Bordon G; Piccand C; Aleandri S; Luciani P; Rössler J; Bernasconi M
Eur J Pharm Biopharm; 2024 Jan; 194():49-61. PubMed ID: 38029941
[TBL] [Abstract][Full Text] [Related]
9. Nucleolin Overexpression Predicts Patient Prognosis While Providing a Framework for Targeted Therapeutic Intervention in Lung Cancer.
Valério-Fernandes Â; Fonseca NA; Gonçalves N; Cruz AF; Pereira MI; Gregório AC; Moura V; Ladeirinha AF; Alarcão A; Gonçalves J; Abrunhosa A; Melo JB; Carvalho L; Simões S; Moreira JN
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565346
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel disrupts polarized entry of membrane-permeable C6 ceramide into ovarian cancer cells resulting in synchronous induction of cell death.
Best C; Calianese D; Szulak K; Cammarata G; Brum G; Carbone T; Still E; Higgins K; Ji F; DI W; Wanebo H; Wan Y
Oncol Lett; 2013 Jun; 5(6):1854-1858. PubMed ID: 23833655
[TBL] [Abstract][Full Text] [Related]
11. Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide.
Øverbye A; Holsæter AM; Markus F; Škalko-Basnet N; Iversen TG; Torgersen ML; Sønstevold T; Engebraaten O; Flatmark K; Mælandsmo GM; Skotland T; Sandvig K
Oncotarget; 2017 Sep; 8(44):76921-76934. PubMed ID: 29100358
[TBL] [Abstract][Full Text] [Related]
12. Click conjugation of peptide to hydrogel nanoparticles for tumor-targeted drug delivery.
Qin M; Zong H; Kopelman R
Biomacromolecules; 2014 Oct; 15(10):3728-34. PubMed ID: 25162488
[TBL] [Abstract][Full Text] [Related]
13. Study and evaluation of nucleolin-targeted delivery of magnetic PLGA-PEG nanospheres loaded with doxorubicin to C6 glioma cells compared with low nucleolin-expressing L929 cells.
Mosafer J; Teymouri M; Abnous K; Tafaghodi M; Ramezani M
Mater Sci Eng C Mater Biol Appl; 2017 Mar; 72():123-133. PubMed ID: 28024568
[TBL] [Abstract][Full Text] [Related]
14. Cell Surface Nucleolin as a Promising Receptor for Effective AS1411 Aptamer-Mediated Targeted Drug Delivery into Cancer Cells.
Mosafer J; Mokhtarzadeh A
Curr Drug Deliv; 2018; 15(9):1323-1329. PubMed ID: 30039760
[TBL] [Abstract][Full Text] [Related]
15. Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer.
Moura V; Lacerda M; Figueiredo P; Corvo ML; Cruz ME; Soares R; de Lima MC; Simões S; Moreira JN
Breast Cancer Res Treat; 2012 May; 133(1):61-73. PubMed ID: 21805188
[TBL] [Abstract][Full Text] [Related]
16. Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer.
Deshpande P; Jhaveri A; Pattni B; Biswas S; Torchilin V
Drug Deliv; 2018 Nov; 25(1):517-532. PubMed ID: 29433357
[TBL] [Abstract][Full Text] [Related]
17. C6-ceramide treatment inhibits the proangiogenic activity of multiple myeloma exosomes via the miR-29b/Akt pathway.
Liu L; Ye Q; Liu L; Bihl JC; Chen Y; Liu J; Cheng Q
J Transl Med; 2020 Aug; 18(1):298. PubMed ID: 32746845
[TBL] [Abstract][Full Text] [Related]
18. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma.
Stover TC; Sharma A; Robertson GP; Kester M
Clin Cancer Res; 2005 May; 11(9):3465-74. PubMed ID: 15867249
[TBL] [Abstract][Full Text] [Related]
19. Immunoliposome-mediated targeting of doxorubicin to human ovarian carcinoma in vitro and in vivo.
Vingerhoeds MH; Steerenberg PA; Hendriks JJ; Dekker LC; Van Hoesel QG; Crommelin DJ; Storm G
Br J Cancer; 1996 Oct; 74(7):1023-9. PubMed ID: 8855969
[TBL] [Abstract][Full Text] [Related]
20. Development of Long-Circulating and Fusogenic Liposomes Co-encapsulating Paclitaxel and Doxorubicin in Synergistic Ratio for the Treatment of Breast Cancer.
Roque MC; Franco MS; Vilela JMC; Andrade MS; de Barros ALB; Leite EA; Oliveira MC
Curr Drug Deliv; 2019; 16(9):829-838. PubMed ID: 31622204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
